Cencora (NYSE:COR) Issues FY 2025 Earnings Guidance

Cencora (NYSE:COR) updated its FY 2025 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of 14.800-15.100 for the period, compared to the consensus estimate of 13.640. The company issued revenue guidance of $314.5 billion-$320.4 billion, compared to the consensus revenue estimate of $292.7 billion. Cencora also updated its FY25 guidance to $14.80-15.10 EPS.

Analyst Ratings Changes

A number of research analysts recently weighed in on the company. Wells Fargo & Company lifted their target price on Cencora from $236.00 to $249.00 and gave the company an “equal weight” rating in a report on Thursday, August 1st. JPMorgan Chase & Co. lifted their price objective on Cencora from $280.00 to $287.00 and gave the company an “overweight” rating in a research note on Wednesday, August 21st. Leerink Partners dropped their target price on shares of Cencora from $277.00 to $275.00 and set an “outperform” rating for the company in a research report on Monday, October 7th. Evercore ISI cut their price target on shares of Cencora from $270.00 to $250.00 and set an “outperform” rating on the stock in a report on Tuesday, October 8th. Finally, Robert W. Baird decreased their price objective on shares of Cencora from $287.00 to $283.00 and set an “outperform” rating for the company in a research note on Friday, September 6th. Three analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $259.44.

Cencora Stock Up 4.9 %

NYSE COR traded up $11.39 on Wednesday, reaching $245.38. The company had a trading volume of 2,208,027 shares, compared to its average volume of 1,409,102. The firm has a market capitalization of $48.35 billion, a PE ratio of 26.64, a P/E/G ratio of 1.49 and a beta of 0.44. The firm has a 50-day moving average of $231.57 and a 200-day moving average of $230.64. Cencora has a 1 year low of $191.11 and a 1 year high of $247.66. The company has a debt-to-equity ratio of 3.93, a current ratio of 0.89 and a quick ratio of 0.55.

Insider Activity

In other news, Chairman Steven H. Collis sold 21,509 shares of the firm’s stock in a transaction dated Tuesday, October 22nd. The stock was sold at an average price of $235.80, for a total transaction of $5,071,822.20. Following the completion of the sale, the chairman now directly owns 285,088 shares in the company, valued at $67,223,750.40. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 15.80% of the company’s stock.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.